Compare ON & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ON | GMAB |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4B | 17.4B |
| IPO Year | 2000 | N/A |
| Metric | ON | GMAB |
|---|---|---|
| Price | $55.26 | $31.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 6 |
| Target Price | ★ $59.04 | $40.40 |
| AVG Volume (30 Days) | ★ 8.8M | 1.4M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 132.41 |
| EPS | 0.75 | ★ 25.10 |
| Revenue | ★ $6,187,800,000.00 | $3,845,670,022.00 |
| Revenue This Year | N/A | $24.85 |
| Revenue Next Year | $6.14 | $16.67 |
| P/E Ratio | $72.51 | ★ $12.31 |
| Revenue Growth | N/A | ★ 29.57 |
| 52 Week Low | $31.04 | $17.24 |
| 52 Week High | $70.58 | $33.65 |
| Indicator | ON | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 59.84 |
| Support Level | $49.13 | $31.32 |
| Resistance Level | $57.52 | $32.41 |
| Average True Range (ATR) | 2.27 | 0.64 |
| MACD | 1.03 | 0.11 |
| Stochastic Oscillator | 78.55 | 73.67 |
Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and the largest supplier of image sensors to the automotive market. While the firm used to be highly vertically integrated, it now pursues a hybrid manufacturing strategy for flexible capacity. Onsemi is pivoting to focus on emerging applications like electric vehicles, autonomous vehicles, industrial automation, and renewable energy.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.